Female Contraceptive Market to Grow with a CAGR of 6.24% through 2030F
Factors such as women and couples prioritizing family
planning and reproductive health is expected to drive the Global Female
Contraceptive Market growth in the forecast period, 2026-2030.
According to TechSci Research report, “Female
Contraceptive Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2030F”, the Global Female Contraceptive
Market stood at USD 15.01 Billion in 2024 and is anticipated to grow with a
CAGR of 6.24% in the forecast period. This can be attributed to
government initiatives and support. Many governments worldwide have recognized
the importance of family planning in controlling population growth and
improving public health. Consequently, they have implemented policies and
programs to promote and subsidize contraceptives, making them more affordable
and accessible to a broader population.
The personalized medicine is making its way into the female
contraceptive market, allowing healthcare providers to tailor contraceptive
recommendations based on an individual's unique health profile and preferences.
Genetic testing and advanced screening techniques can help identify which
contraceptive methods are most suitable for a woman, minimizing the risk of
adverse effects and improving overall satisfaction.
Several factors are driving market growth, including a rise in sexually transmitted diseases (STDs), an increased rate of unintended pregnancies, and the implementation of government initiatives. Globally, the number of unintended pregnancies is on the rise, with significant global implications. For example, according to the United Nations Population Fund, as of March 2022, approximately half of all pregnancies worldwide are unintended, totaling 121 million annually. More than 60% of these unplanned pregnancies result in abortions, with an estimated 45% of all abortions categorized as unsafe, leading to 5%–13% of all maternal fatalities and jeopardizing progress toward the "Sustainable Development Goals".mior A study published in BMC Pregnancy and Childbirth in 2021 by Nebamallika Dahingia found that unintended pregnancies impact roughly 85 million women globally, with India accounting for more than one in seven of these cases. Uttar Pradesh, India's most populous state, with a population of approximately 200 million, exhibits a higher rate of unwanted fertility compared to the rest of the country. Consequently, the increasing incidence of unintended pregnancies is anticipated to drive growth in the female contraceptive market.
The escalating prevalence of STDs among the population is expected to contribute to market growth. For instance, data published by the World Health Organization in November 2021 revealed that in 2020, there were approximately 374 million new infections of four major sexually transmitted diseases: chlamydia (129 million), gonorrhea (82 million), syphilis (7.1 million), and trichomoniasis (156 million). Consequently, the growing burden of STDs is expected to heighten the demand for contraception to prevent disease transmission, thereby stimulating market growth.
Various countries and their respective governments have recognized the need to address the increasing rates of unintended pregnancies, launching numerous initiatives aimed at educating and preventing unwanted abortions and pregnancies. Contraceptive pill usage is one such initiative, and it is supported by the fundamental right to privacy guaranteed by the United States Constitution. For example, the United States Agency for International Development (USAID) promotes and backs voluntary family planning and reproductive health programs in approximately 40 countries worldwide. Consequently, government initiatives are fostering the adoption of contraceptive methods to prevent unnecessary births and abortions.
Nevertheless, the female contraceptive market may face constraints in the form of the high cost of devices and treatment, as well as potential side effects associated with contraceptive drugs and devices, which could impede market growth in the forecast period.
Browse over XX market data Figures spread through XX
Pages and an in-depth TOC on "Global Female Contraceptive Market.”
The Global Female Contraceptive Market is segmented into
contraceptive drugs, device, regional distribution, and company.
Based on device, the sub-dermal contraceptive implants
segment is expected to witness significant growth in the female contraceptive
market owing to the factors such as rising unwanted pregnancies, high clinical
effectiveness, and high adoption rate among the population. There are two types
of sub-dermal implants - Etonogestrel Implant, Levonorgestrel Implant. Under
sub-dermal contraceptive implants, the Etonogestrel implants are likely to
witness significant growth. Etonogestrel is a hormone that prevents ovulation.
This medication also causes changes in the cervical mucus and uterine lining,
making it harder for sperm to reach the uterus and harder for a fertilized egg
to attach to the uterus. Subdermal Etonogestrel implant is used as
contraception to prevent pregnancy. The medicine is contained in a small
plastic rod that is implanted under the skin of the upper arm. The medicine is
released slowly into the body. The rod can remain in place and provide
continuous contraception for up to 3 years. The increasing company focus on adopting various business
strategies such as product launches, listing products in the countries,
mergers, and company spin-offs are likely to boost the growth of the market
over the forecast period.
Based on region, the Asia-Pacific region is the
fastest-growing market in the global female contraceptive sector due to several
key factors. Rapid population growth, increasing awareness of reproductive
health, and rising government initiatives to promote family planning have
significantly boosted demand. Countries like India and China are implementing
large-scale public health campaigns and improving access to contraceptives
through both public and private healthcare channels. Urbanization, improved female
education, and workforce participation are also driving greater adoption of
contraceptive methods. Expanding healthcare infrastructure, supportive policy
frameworks, and the presence of low-cost manufacturing hubs make the region
attractive for global contraceptive manufacturers and suppliers.
Major companies operating in Global Female
Contraceptive Market are:
· Bayer AG
· Mayer Laboratories Inc
· Pfizer Inc
· Mylan Pharmaceuticals Inc
· Teva Pharmaceutical Industries Ltd
· Organon & Co.
· Agile Therapeutics Inc
· Lupin Pharmaceuticals Inc
· The Female Health Company
· FUJI LATEX CO.,LTD.
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“The global female contraceptive market is undergoing a
transformation driven by innovation, technology, and evolving societal needs.
The upcoming key trends in the market encompass a wide range of options, from
reducing side effects and expanding non-hormonal alternatives to incorporating
digital health solutions and promoting sustainability. These trends reflect the
industry's commitment to meeting the diverse needs and preferences of women
worldwide while striving to enhance the effectiveness, accessibility, and
overall user experience of female contraceptives. As the global female
contraceptive market continues to evolve, it promises to empower women with
more choices and greater control over their reproductive health,” said Mr.
Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Female Contraceptive Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides), By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others), By Region & Competition, 2020-2030F”, has evaluated the future growth potential
of Global Female Contraceptive Market and provides statistics & information
on market size, structure and future market growth. The report intends to
provide cutting-edge market intelligence and help decision makers take sound
investment decisions. Besides, the report also identifies and analyzes the
emerging trends along with essential drivers, challenges, and opportunities in
Global Female Contraceptive Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com